00:20 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Cassiopea planning NDA for acne candidate after Phase III meets endpoints

Cassiopea S.p.A. (SIX:SKIN) said twice-daily topical Winlevi 1% clascoterone (CB-03-01) for 12 weeks met the three co-primary endpoints vs. placebo in both the Phase III Study 25 and Study 26 to treat acne. The company...
22:10 , Aug 3, 2018 |  BC Extra  |  Politics & Policy

ICER announces preliminary 2019 topics

The Institute for Clinical and Economic Review (ICER) released Thursday a preliminary list of drugs and other healthcare interventions that it may review in 2019. ICER's selection criteria include the projected timing and likelihood of...
17:16 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Sienna's acne photoparticle therapy misses in two pivotal trials

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) said SNA-001 missed the primary and secondary endpoints in a pair of pivotal trials to treat moderate to severe acne vulgaris. The candidate is a topical photoparticle therapy targeting the sebaceous gland...
15:38 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Reata reports retained benefit in Phase II CKD trial

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported Phase II data showing that chronic kidney disease (CKD) patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR) four weeks after discontinuing treatment. In 25 patients...
22:30 , Jul 23, 2018 |  BC Extra  |  Clinical News

Reata gains on retained benefit in CKD trial, proposes follow-on

Reata Pharmaceuticals Inc. (NASDAQ:RETA) added $30.15 (65%) to $76.55 on Monday after reporting Phase II data showing that chronic kidney disease patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR)...
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on June 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform,...
18:50 , Jul 11, 2018 |  BC Extra  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Calliditas raises over $70M in Swedish IPO

Renal disease company Calliditas Therapeutics AB (SSE:CALTX) raised SEK650 million ($73.4 million) on June 15 through the sale of 14 million shares at SEK45 in an IPO on NASDAQ Stockholm. The company expects to begin...
17:45 , May 11, 2018 |  BC Week In Review  |  Clinical News

Sol-Gel's acne candidate meets in Phase II

In February, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) said once-daily low- and high-dose topical cream TWIN (S6G5T) both met the three co-primary endpoints compared with vehicle in a Phase II trial in 726 patients with acne. Data...
17:44 , May 11, 2018 |  BC Week In Review  |  Clinical News

Sol-Gel reports Phase II data for Epsolay in rosacea

In February, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) said once-daily Epsolay (formerly VERED) met the co-primary endpoints in a Phase II trial in 92 patients with rosacea. Data from the double-blind, U.S. trial were presented at the...